Posted by Michael Wonder on 03 May 2022
Boehringer Ingelheim Canada announces reimbursement for Ofev (nintedanib) in seven public drug plans for the treatment of progressive fibrosing interstitial lung diseases
3 May 2022 - Boehringer Ingelheim is pleased to announce that Ofev (nintedanib), is now available for public reimbursement in Quebec, Ontario, Alberta, New Brunswick, Newfoundland and Labrador, Northwest Territories, and through the Non-Insured Health Benefits program for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype (also known as.
Results of the INBUILD clinical trial showed that Ofev slowed the rate of lung function decline by 57% across the overall study population versus placebo.
